Ministry of Health and Long-Term Care

Drugs and Devices Division

Drug Submission Status

Report for February 2019

Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via a DDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Auro Pharma Inc.	Auro-Atomoxetine	Strattera	atomoxetine HCl	80mg	capsule	02471531
Auro Pharma Inc.	Auro-Atomoxetine	Strattera	atomoxetine HCl	100mg	capsule	02471558
Natco Pharma (Canada) Inc.	Nat-Erlotinib	Tarceva	erlotinib	25mg	tablet	02483912
Natco Pharma (Canada) Inc.	Nat-Erlotinib	Tarceva	erlotinib	100mg	tablet	02483920

Ontario

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Natco Pharma (Canada) Inc.	Nat-Erlotinib	Tarceva	erlotinib	150mg	tablet	02488393
Pharmaris Canada Inc	PRZ-Sildenafil	Viagra	sildenafil	100mg	FC tablet	02468557
Taro Pharmaceuticals Inc.	Taro-Imiquimod Pump	Aldara P	imiquimod	5% w/w	topical cream	02482983
Teva Canada Limited	Teva-Fulvestrant Injection	Faslodex	fulvestrant	50 mg/ mL	IM solution	02460130